Novo Nordisk's diabetes drug liraglutide stumbles on thyroid cancer concerns
This article was originally published in Scrip
Executive Summary
Novo Nordisk's GLP-1 analogue Victoza (liraglutide) injection does not present an excessive cardiovascular risk, but questions about thyroid carcinogenicity may preclude approval of the agent for type 2 diabetes, the US FDA's outside experts have said.